Lilly's Foundayo Sees Modest Launch with Just 1,390 Prescriptions in Debut Week

Key Takeaways:

• Eli Lilly's new oral obesity pill Foundayo recorded only 1,390 prescriptions in its debut week
• This compares to Novo's oral Wegovy reaching 50,000 weekly prescriptions within three weeks of launch
• The modest uptake suggests challenges in competing with established oral GLP-1 options despite Foundayo's advantages
• Being first to market and brand recognition appear crucial for success in the competitive GLP-1 space

Foundayo's Surprising Slow Start

Eli Lilly's new oral obesity pill, which recorded only 1,390 prescriptions in its debut week — a slow start that helps preserve Novo's lead in the GLP-1/weight-loss market. The numbers represent a stark contrast to the explosive launch many analysts anticipated for Foundayo (orforglipron), which received FDA approval on April 1st under an accelerated review process.

The prescription data comes as a surprise given Foundayo's competitive advantages over existing oral options. Unlike Novo Nordisk's oral Wegovy, which requires taking on an empty stomach with a 30-minute wait before eating, Lilly's Foundayo doesn't have those restrictions. Taken with or without food, the Lilly drug still has the same effect.

Novo's Oral Wegovy Success Story

To understand the significance of Foundayo's modest debut, it's important to compare it with Novo Nordisk's oral launch success. Novo Nordisk is first to market with a GLP-1 pill for obesity, and it hit 50,000 weekly prescriptions in under three weeks of its launch. Since its U.S. debut in early January, Wegovy pill sales have soared. More than 600,000 prescriptions were written in the first two months alone, the drugmaker said, with many of them going to patients new to GLP-1 drugs.

The contrast is striking: while Novo's oral Wegovy reached 50,000 prescriptions weekly within three weeks, Foundayo managed less than 1,400 in its entire first week. This difference suggests that being first to market provides significant advantages, even when a competitor offers superior convenience features.

Why the Slow Uptake?

Several factors may explain Foundayo's modest launch numbers. JPMorgan analysts wrote in an April 1 note that Lilly's Foundayo likely won't be adopted as quickly. Novo benefited from being first to market and from immediate name recognition because its pill has the same brand name as the injectable.

The brand recognition factor is crucial. People and doctors already know "Wegovy" from the successful injectable version, making the transition to "Wegovy pill" intuitive. Foundayo, however, introduces an entirely new brand name that requires education and awareness-building.

Additionally, the FDA requested additional safety data from Lilly on its Foundayo launch, a near-term regulatory hiccup for Lilly that can indirectly help Novo by slowing competitor momentum. While the safety request doesn't prevent prescribing, it may create hesitation among some providers who prefer to wait for additional data.

Market Implications and Future Competition

Despite the slow start, analysts haven't written off Foundayo's long-term potential. Though Lilly is late to the party, the demand for GLP-1 pills combined with Foundayo's advantages means it could have what it takes to become "the market leading oral, especially internationally," the JPMorgan note predicts. Brokerages estimate Foundayo will see sales of anywhere from $1.5 billion to $2.8 billion this year, Reuters reported.

The oral GLP-1 market represents a significant opportunity. Pills are the next battleground for the two companies, which established the booming GLP-1 space that some analysts say could be worth roughly $100 billion by the 2030s. Goldman Sachs analysts said in August that oral drugs could capture a 24% share — or around $22 billion — of the 2030 global weight loss drug market.

What This Means for You

If you're considering oral GLP-1 options, Foundayo's modest uptake actually works in your favor by providing more choice and potentially better availability. While Novo's oral Wegovy has seen such high demand that some pharmacies experience stock issues, Foundayo's slower launch means better initial availability.

The key advantages of Foundayo—no food restrictions and flexible timing—remain significant for many people. If you've struggled with the strict morning routine required for oral Wegovy, Foundayo might offer the convenience you need to maintain consistent treatment. You can learn more about different GLP-1 medications to compare your options.

For those comparing costs, both oral options start at $149 monthly for self-pay customers, making them more accessible than injectable versions that typically cost $299-$499 monthly out of pocket. You can compare costs across different GLP-1 medications to find the most affordable option for your situation.

To get started with either oral option, consider working with healthcare providers who specialize in weight management and can help you navigate the choice between different treatments based on your lifestyle and preferences.

Expanding the Treatment Market

"Overall, we continue to believe that injectable anti-obesity medications will retain the majority of market share (roughly 80%, based on our estimates) in the United States due to the high potency of injectables coupled with a more elevated U.S. [body mass index] population," Hsieh wrote in a research note. "Based on initial feedback from the oral Wegovy launch, patients who are currently on oral GLP-1 receptor agonists are treatment-naive, suggesting the potential for the oral drug class to expand the [total addressable market]."

This suggests that oral GLP-1s like Foundayo may primarily attract new people rather than switching existing users from injectables, potentially expanding overall access to GLP-1 treatment. For many, the convenience of a pill versus an injection could be the deciding factor in starting treatment.

The slow but steady growth of oral options means more people may find GLP-1 treatment approachable, especially those who have been hesitant about injections. As both companies continue to refine their oral formulations and build awareness, we can expect to see steady growth in this segment of the market.